Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-03-06
Disclosure Type: Single Sales/Supply Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has substantially increased its biopharmaceutical contract manufacturing organization (CMO) contract with global pharmaceutical company UCB from approximately KRW 45.1 billion to KRW 427 billion. Concurrently, the regulatory non-disclosure option regarding the client’s identity and contract duration—originally scheduled through late 2025—has been lifted early.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Counterparty: UCB (Disclosed early following the removal of management confidentiality restrictions)
- Contract Type: Biopharmaceutical Contract Manufacturing Organization (CMO) Contract
- Contract Amount (Amended):
- (Before) KRW 45,107,116,600 (USD 41,654,000)
- (After) KRW 427,002,630,600 (USD 394,314,000)
- Net Increase: Increased by USD 352,660,000 (Approx. KRW 381.9B) at the request of the client.
- Exchange Rate: Calculated by applying the initial exchange rate of 1,082.90 KRW/USD from the original contract disclosure date (December 21, 2017).
- Proportion to Annual Revenue (Amended):
- (Before) 15.31% → (After) 144.93%
- The baseline annual revenue (KRW 294,622,020,774) reflects the company’s historical metrics from the initial filing period.
- Contract Period (Amended):
- December 21, 2017 – December 31, 2030 (The contract end date has been explicitly disclosed as late 2030, subject to change upon mutual agreement).
- Non-Disclosure Status (Amended):
- (Before) Expiration Date 2025-12-31 → (After) Deleted (Non-disclosure lifted).
- Other Details: This agreement represents the formalized main contract corresponding to the “Material Management Matters Related to Investment Decisions” initially disclosed on May 4, 2017.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
- Impact on Fundamental Changes: Unlike routine administrative updates, this disclosure underscores a significant fundamental upgrade with a material upward revision of a contract total by more than KRW 381.9 billion. By lifting the total contract value with UCB to KRW 427 billion through late 2030, this update expands the long-term revenue pipeline, which may generate a positive potential impact on financial metrics over the contract duration.
- Risks and Red Flags for Investors: While the contract value has been adjusted upward and the partner’s identity (UCB) has been disclosed early, the regulatory filing does not specify the concrete operational causes behind the adjustment, meaning market participants should avoid speculative conclusions. Additionally, because the monetary figures remain anchored to the historical 2017 exchange rate of 1,082.90 KRW/USD, actual reported revenue could vary depending on spot exchange rates during active billing periods. Furthermore, as the contract end date is subject to change based on mutual agreement, the timeline for long-term revenue recognition may remain fluid.
📝 Editor’s Comment (by K-STOCK Editor)
An extraordinary upward amendment has been finalized, multiplying the size of the existing contract by over nine times (from KRW 45.1 billion up to KRW 427 billion)! The early removal of the non-disclosure status—fully unmasking global Big Pharma partner UCB and extending the formalized operational layout through 2030 well ahead of the original 2025 schedule—presents a clear operational linkage. As the cumulative size of this long-term deal has expanded significantly, market participants may focus heavily on this expanded baseline, though investors will want to observe carefully how this adjustment translates into long-term potential impacts.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
